Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Serina Therapeutics ( (SER) ) is now available.
Serina Therapeutics announced that its 2025 annual meeting of stockholders will be held on November 7, 2025. The change in the meeting date from the previous year affects the deadline for stockholder proposals, which is set for August 15, 2025. This adjustment provides stakeholders with a new timeline for submitting proposals and nominations, ensuring compliance with regulatory requirements and the company’s bylaws.
The most recent analyst rating on (SER) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.
Spark’s Take on SER Stock
According to Spark, TipRanks’ AI Analyst, SER is a Neutral.
The overall stock score reflects significant financial challenges, balanced by positive corporate developments. The most critical factor is the poor financial performance, which is a major concern. However, recent technological breakthroughs and funding initiatives show promise and potential for future growth, providing some support to the stock’s outlook.
To see Spark’s full report on SER stock, click here.
More about Serina Therapeutics
Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug product candidates for neurological diseases and other indications. Their POZ PlatformTM aims to enhance the efficacy and safety of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-based drug conjugates. The company is based in Huntsville, Alabama, at the HudsonAlpha Institute of Biotechnology.
Average Trading Volume: 13,335
Technical Sentiment Signal: Sell
Current Market Cap: $61.5M
Find detailed analytics on SER stock on TipRanks’ Stock Analysis page.